



SUVEN LIFE SCIENCES LTD

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvlen.com website: www.suvlen.com

STATEMENT OF STANDALONE & CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st March 2016

PART - I

Sl. No.	PARTICULARS	For the Quarter Ended			Current year ended		Rs. in Lakhs
		31-Mar-2016	31-Dec-2015	31-Mar-2015	31-Mar-2016	31-Mar-2016	Previous Year Ended
		Audited	Un-audited	Audited	Audited	Audited	Audited
1	Income from operations				Standalone	Consolidated	
	(a) Net sales/Income from operations (Net of excise duty)	16,927.53	11,250.43	11,066.25	49,952.24	49,952.24	52,085.50
	(b) Other operating income	-	-	-	-	-	-
	Total income from operations (net)	16,927.53	11,250.43	11,066.25	49,952.24	49,952.24	52,085.50
2	Expenses						
	a) Cost of materials consumed	4,664.35	4,180.63	4,547.61	17,845.37	17,845.37	17,724.78
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,925.08	(413.63)	(661.28)	(1,205.21)	(1,205.21)	347.95
	d) Employee benefits expense	943.78	1,158.02	995.18	4,163.59	4,163.59	3,651.16
	e) Depreciation and amortisation expense	479.82	451.96	244.71	1,672.04	1,672.04	1,177.58
	f) Other expenses - Manufacturing Exps	2,162.55	1,799.32	1,639.72	7,446.06	7,446.06	6,444.21
	- R & D Exps	1,678.23	1,516.96	1,359.31	6,295.08	9,112.83	5,596.26
	- Others	1,268.83	545.58	735.82	3,081.90	3,086.86	2,375.29
	Total expenses	13,122.64	9,238.84	8,861.07	39,298.83	42,121.54	37,317.23
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	3,804.89	2,011.59	2,205.18	10,653.41	7,830.70	14,768.27
4	Other Income	451.75	397.00	381.07	1,935.02	1,935.02	858.12
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	4,256.64	2,408.59	2,586.25	12,588.43	9,765.72	15,626.39
6	Finance costs	156.08	153.86	120.96	541.70	542.11	470.92
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	4,100.56	2,254.73	2,465.29	12,046.73	9,223.61	15,155.47
8	Exceptional Items	-	-	200.44	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7 ± 8)	4,100.56	2,254.73	2,264.85	12,046.73	9,223.61	15,155.47
10	Tax Expenses	871.44	482.80	569.95	2,549.75	2,549.75	4,280.44
11	Net Profit/ (Loss) from Ordinary Activities after tax (9 ± 10)	3,229.12	1,771.93	1,694.90	9,496.98	6,673.86	10,875.03
12	Extraordinary Items (net of tax expense ₹ ____ Lakhs)	-	-	-	-	-	-
13	Net Profit (+)/Loss(-) for the period (11 ± 12)	3,229.12	1,771.93	1,694.90	9,496.98	6,673.86	10,875.03
14	Share of profit / (loss) of associates*	-	-	-	-	-	-
15	Minority interest *	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 ± 14 ± 15) *	3,229.12	1,771.93	1,694.90	9,496.98	6,673.86	10,875.03
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				61,091.58	58,272.72	54,658.58
19.i	Earning Per Share (EPS) (before extraordinary items) (of ₹ Rs.1/- each) (not annualised):						
	a) Basic	2.54	1.39	1.41	7.46	5.24	9.04
	b) Diluted	2.54	1.39	1.41	7.46	5.24	9.04
19.ii	Earning Per Share (EPS) (after extraordinary items) (of ₹ Rs.1/- each) (not annualised):						
	a) Basic	2.54	1.39	1.41	7.46	5.24	9.04
	b) Diluted	2.54	1.39	1.41	7.46	5.24	9.04

PART - II							
A	PARTICULARS OF SHAREHOLDING						
1	Public share holdings						
	- Number of shares	50,912,478	51,462,478	51,624,902	50,912,478	50,912,478	51,624,902
	- Percentage of Share holding	40.00%	40.43%	40.56%	40.00%	40.00%	40.56%
2	Promoters and promoter group Shareholding**						
	a) Pledged / Encumbered	NIL	NIL	NIL	NIL	NIL	NIL
	- Number of shares						
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL
	b) Non-Encumbered	76,370,000	75,820,000	75,657,576	76,370,000	76,370,000	75,657,576
	- Number of shares						
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	60.00%	59.57%	59.44%	60.00%	60.00%	59.44%
	Particulars	31-Mar-2016					
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter	0					
	Received during the quarter	29					
	Disposed of during the quarter	29					
	Remaining unresolved at the end of the quarter	0					

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED							Rs. In Lacs
1	SEGMENT REVENUE :-	Quarter Ended			Current year ended		Year Ended
		31-Mar-2016	31-Dec-2015	31-Mar-2015	31-Mar-2016	31-Mar-2016	31-Mar-2015
		Audited	Un-audited	Audited	Audited	Audited	Audited
					Standalone	Consolidated	
	a) Manufacturing (GRAMS)	16,410.89	10,252.62	10,785.75	46,710.87	46,710.87	50,016.03
	b) Services (DDDSS)	516.64	997.81	280.50	3,241.37	3,241.37	2,069.47
	c) Research & Development	-	-	-	-	-	-
	Net Sales from Operations	16,927.53	11,250.43	11,066.25	49,952.24	49,952.24	52,085.50
2	SEGMENT RESULTS :-						
	Profit/(Loss) before tax and interest:						
	a) Manufacturing (GRAMS)	6,196.44	3,310.74	3,956.73	17,327.83	17,327.83	21,125.81
	b) Services (DDDSS)	277.15	622.30	166.12	1,946.77	1,946.46	1,113.29
	c) Research & Development	(1,678.23)	(1,516.97)	(1,537.46)	(6,295.08)	(9,112.83)	(5,596.26)
	TOTAL	4,795.36	2,416.07	2,585.39	12,979.52	10,161.46	16,642.84
Less:	i) Interest	98.48	107.66	61.28	361.00	361.00	286.05
	ii) Other Un-allocable exps net off un-allocable Income	596.32	53.68	259.26	571.79	576.85	1,201.32
	Total Profit Before Tax	4,100.56	2,254.73	2,264.85	12,046.73	9,223.61	15,155.47
3	CAPITAL EMPLOYED						
	(Segment Assets - Segment Liabilities)						
	a) Manufacturing (GRAMS)	35,227.81	40,455.95	28,252.47	35,227.81	35,112.22	28,252.47
	b) Services (DDDSS)	3,540.29	3,314.19	3,612.25	3,540.29	3,535.15	3,612.25
	c) Research & Development	956.18	239.23	558.65	956.18	496.96	558.65
	d) Un allocated	30,645.09	27,167.79	32,151.43	30,645.09	28,406.28	32,151.43
	TOTAL	70,369.37	71,177.16	64,574.80	70,369.37	67,550.61	64,574.80

- Notes: 1) The above results were reviewed by Audit committee and approved by the Board of Directors' meeting held on 27th May 2016
- 2) Corresponding Previous period figures have been regrouped / reclassified whenever necessary.
- 3) The above results were reviewed by Auditors .
- 4) Suvan Inc., the subsidiary, has been incorporated on 15th Sept, 2015 hence the consolidated figures are presented for the current year.

Place: Hyderabad
Date : 27th May, 2016



For SUVEN LIFE SCIENCES LTD

(Signature)

D.G. PRASAD

Director

DIN: 00160408

We Deliver



SUVEN LIFE SCIENCES LTD

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500
034 CIN: L24110TG1989PLC009713

Statement of Assets & Liabilities


(Rs. in lakhs)

	Particulars	Standalone	Consolidated	Standalone
		31/03/2016	31/03/2016	31/03/2015
A	EQUITY AND LIABILITIES			
1	Shareholder's funds:			
	(a) Share Capital	1,272.82	1,272.82	1,272.82
	(b) Reservs and Surplus	61,091.58	58,272.82	54,658.58
	Sub-total - Shareholders' funds	62,364.40	59,545.64	55,931.40
2	Non-current liabilities			
	(a) Long-term borrowings	4,322.66	4,322.66	6,144.60
	(b) Long-term provisions	239.49	239.49	227.48
	(c) Deferred tax Liability (net)	3,442.81	3,442.81	2,271.33
	Sub-total - Non-current liabilities	8,004.96	8,004.96	8,643.41
3	Current liabilities			
	(a) Short-term borrowings	2,416.36	2,416.36	2,823.51
	(b) Trade payables	3,533.11	3,533.11	4,389.08
	(c) Other current liabilities	4,198.25	4,788.85	4,244.59
	(d) Short-term provisions	274.50	274.50	1,281.42
	Sub-total - Current liabilities	10,422.22	11,012.82	12,738.60
	TOTAL - EQUITY AND LIABILITIES	80,791.58	78,563.42	77,313.41
B	ASSETS			
1	Non-current assets			
	(a) Fixed assets	31,255.07	31,255.07	27,896.24
	(b) Non-current investments	2,298.10	-	-
	(c) Long-term loans and advances	409.49	409.49	1,088.74
	(d) Other non-current assets	160.53	160.53	630.54
	Sub-total - Non-current assets	34,123.19	31,825.09	29,615.52
2	Current assets			
	(a) Current investments	3.64	3.64	3.64
	(b) Inventories	8,346.44	8,346.44	8,180.55
	(c) Trade receivables	5,356.49	5,356.49	4,016.92
	(d) Cash and cash equivalents	24,063.79	24,133.73	27,968.90
	(e) Short-term loans and advances	8,865.80	8,865.80	7,459.80
	(f) Other current assets	32.23	32.23	68.08
	Sub-total - Current assets	46,668.39	46,738.33	47,697.89
	TOTAL - ASSETS	80,791.58	78,563.42	77,313.41

Note: Suven Inc., the subsidiary, has been incorporated on 15th Sept 2015 hence the cosolidation figures are presented for the current year .

For Suven Life Sciences Ltd




D.G. Prasad
Director
DIN: 00160408



Auditor's Report on Quarterly Financial Results and Year to Date Results of Suven Life Sciences Limited Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors of **Suven Life Sciences Limited**

We have audited the quarterly financial results of **Suven Life Sciences Limited** ('the Company') for the quarter ended 31st March, 2016 and the year to date results for the period from 1st April, 2015 to 31st March, 2016, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS-25), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India.


We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the **NET PROFIT** and other financial information for the quarter ended 31st March, 2016 as well as the year to date results for the period from 1st April, 2015 to 31st March, 2016.

for **KARVY & CO.**,
Chartered Accountants
ICAI Firm Regn. No.001757S

K. AJAY KUMAR
Partner
M. No. 021989



Place: Hyderabad
Date : 27/05/2016



Auditor's Report on Quarterly Consolidated Financial Results and Consolidated Year to Date Financial Results of Suven Life Sciences Limited, pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of **Suven Life Sciences Limited**

We have audited the quarterly consolidated financial results of **Suven Life Sciences Limited** ('the Company') for the quarter ended 31st March, 2016 and the consolidated year to date results for the period from 1st April, 2015 to 31st March, 2016, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These consolidated quarterly financial results as well as the consolidated year to date financial results have been prepared from consolidated interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of such consolidated interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS-25), mandated under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

We did not audit the financial statements of one subsidiary included in the consolidated quarterly financial results and consolidated year to date results, whose consolidated interim financial statements reflect total assets of Rs.69.94 Lakhs as at 31st March, 2016 and the total revenue of Rs.-Nil- as at 31st March, 2016. These interim financial statements and other financial information have been audited by other auditor whose report has been furnished to us, and our opinion on the quarterly financial results and the year to date results, to the extent they have been derived from such interim financial statements is based solely on the report of such other auditor.

In our opinion and to the best of our information and according to the explanations given to us, these consolidated quarterly financial results as well as the consolidated year to date financial results:

- (i) include the quarterly financial results and year to date financial results of the following entities:
 - (a) SUVEN INC – Wholly Owned Subsidiary
- (ii) have been presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (iii) give a true and fair view of the consolidated **NET PROFIT** and other financial information for the quarter ended 31st March, 2016 as well as the consolidated year to date results for the period from 1st April, 2015 to 31st March, 2016






For **KARVY & CO.**,
Chartered Accountants
ICAI Firm Regn. No.001757S


K. AJAY KUMAR
Partner
M.No.021989



Place: Hyderabad
Date : 27/05/2016

FORM – A
 (for audit report with unmodified opinion)
 (Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015)

1.	Name of the Company:	SUVEN LIFE SCIENCES LIMITED
2.	Annual financial statements for the year ended	31st March 2016 (Standalone and Consolidated)
3.	Type of Audit observation	Un-modified
4.	Frequency of observation	Not Applicable
5.	<p style="text-align: center;"><i>Signed by-</i></p> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p style="text-align: center;">For Suven Life Sciences Limited</p>  <p style="text-align: center;">Venkateswarlu Jasti Chairman & CEO DIN: 00278028</p> </div> <div style="width: 45%;"> <p style="text-align: center;">For Suven Life Sciences Limited</p>  <p style="text-align: center;">D G Prasad Chairman of Audit Committee DIN: 00160408</p> </div> </div> <div style="display: flex; justify-content: center; margin: 10px 0;">  </div> <div style="display: flex; justify-content: space-between; margin-top: 20px;"> <div style="width: 45%;"> <p style="text-align: center;">For Suven Life Sciences Limited</p>  <p style="text-align: center;">P. Subba Rao Chief Financial Officer M. No. A11342</p> </div> <div style="width: 45%;"> <p style="text-align: center;">For KARVY & Co., Chartered Accountants FRN: 01757S</p>  <p style="text-align: center;">K. AJAY KUMAR Partner M. No. 021989</p> </div> </div>	

Place: Hyderabad
 Date: 27th May, 2016

News Release

Suven Revenue up by 49.21%; PAT up by 83.23% for the Fourth quarter ended March 2016

HYDERABAD, INDIA (27 May' 2016) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specialized in CRAMS for global life science companies and drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 31st March 2016. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 27th May' 2016 at Hyderabad.

Financial Highlights for the 4th Quarter ended March' 2016 (QoQ):

Growth in income	INR 1738 Mn vs 1165 Mn - up by 49%
Growth in PAT	INR 323 Mn vs 177 Mn - up by 82%
Growth in EBIDTA	INR 474 Mn vs 286 Mn - up by 66%

Financial Highlights for the year ended March' 2016:

Growth in income	INR 5189 Mn vs 5294 Mn - down by 2%
Growth in PAT	INR 950 Mn vs. 1088 Mn - down by 13%
Growth in EBIDTA	INR 1426 Mn vs 1680 Mn - down by 15%

Suven's expenses on innovative R&D in Drug Discovery stood at INR 630 Mn (12% on revenue) for the year ended Mar' 2016.

On consolidation of the accounts of Suven, Inc., USA, the wholly owned subsidiary, the PAT reduced to INR 667 Mn and expenditure on R&D increased to INR 911 Mn.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

Suven Life Sciences Limited